Bio-Rad Laboratories, Inc. Class A BIO

Biologics, biosimilars and personalized therapies are fueling CDMO outsourcing, while AI, automation and single-use systems enable scalable, compliant protein production.Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Manufacturing Services Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Recombinant Proteins Manufacturing Services Market to Reach US$15.3 Billion by 2030 The global recombinant proteins manufacturing services m

Bio-Rad Laboratories (BIO) has drawn attention after recent share performance data showed a decline of about 2% over the past month, alongside a gain of roughly 27% over the past three months. At a share price of US$377.71, Bio-Rad Laboratories has seen short term share price momentum cool over the past month. However, the 90 day share price return of about 27% and 1 year total shareholder return of roughly 27% suggest sentiment has improved compared with the much weaker 5 year total...

Demand is rising in diagnostics, precision medicine and biopharma research, while nanotechnology, automation and AI unlock targeted therapies and high-throughput workflows.Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Magnetic Beads - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global magnetic beads market was valued at an estimated US$3.3 billion in 2025 and is projected to reach US$7.4 billion by 2032, advancing at a compound annual growth rate (CAG

Opportunities include automated closed systems, AI-enabled quality control, single-cell and cell therapy workflows, precision medicine, advanced diagnostics and emerging-market expansion.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Cell Isolation/Cell Separation Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The market research report examines the global Cell Isolation/Cell Separation Market, which is projected to reach USD 6.97 billion in 2026 and grow a

Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.

Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertiseLOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions intended to support cancer centers and clinical laboratories. Both solutions detect circulating tum

Personalized medicine and chronic disease care are driving demand for TDM, with opportunities in consumables, automation, point-of-care devices, AI software and pharmacogenomics.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Therapeutic Drug Monitoring - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Therapeutic Drug Monitoring was estimated at US$1.5 Billion in 2025 and is projected to reach US$2.6 Billion by 2032, growing at a CAGR of 8

Demand is rising for real-time biomolecular analysis in drug discovery and diagnostics, driven by SPR/BLI advances, automation, high-throughput screening and biomarker research.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Label-free Array Systems - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Label-free Array Systems was valued at US$1.8 Billion in 2024 and is projected to reach US$2.4 Billion by 2030, growing at a CAGR of 5.6% from 2

HERCULES, Calif., September 16, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM Eastern Time.

Bio-Rad Laboratories has delivered a sharp mix of outcomes for long term holders, with the stock down about 52.9% over 5 years even as shorter term returns have turned positive. This puts the spotlight on what its current share price implies about the cash the business can generate. With the valuation lens focused on cash flows through a Discounted Cash Flow (DCF) framework, the question is how well today's market price lines up with the stream of money the company may produce for...

The global transcriptome sequencing market is projected to reach $11.8 billion by 2035, growing at a 7.3% CAGR from 2025 to 2035. Growth is driven by falling sequencing costs, precision medicine, drug discovery, biomarker development, single-cell and spatial transcriptomics, long-read RNA sequencing, and AI-powered analytics. Consumables, bulk RNA-seq, drug discovery applications, and pharmaceutical and biotechnology companies led the market in 2025. North America held the largest regional share

A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.

The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher

HERCULES, Calif., August 31, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo’s 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time).